Crescent Biopharma Inc (CBIO)

$17.28 -0.72 (-4.00%)
Market Cap 496.03M
Revenue (ttm) 10.84M
Net Income (ttm) -153.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,420.11%
Debt to Equity Ratio 0.00
Volume 238,200
Avg Vol 293,292
Day's Range N/A - N/A
Shares Out 27.56M
Stochastic %K 13%
Beta 1.16
Analysts Strong Sell
Price Target $31.67

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 460 5595
Address:
300 Fifth Avenue, Waltham, United States
MorenitaScorp
MorenitaScorp Jun. 8 at 1:58 AM
$CBIO ⌚️
0 · Reply
focafoca99
focafoca99 Jun. 3 at 1:26 PM
$CBIO recorded its annual meeting voting results, electing two Class II directors and approving key shareholder proposals.
0 · Reply
focafoca99
focafoca99 May. 22 at 12:14 AM
$CBIO previewed its ASCEND trial poster for the ASCO 2026 meeting.
0 · Reply
outlawinvestor1
outlawinvestor1 May. 16 at 10:04 AM
updated paragon family of extended life biologics. https://www.paragontherapeutics.com/ $APGE $SYRE $ORKA $JBIO $CBIO
1 · Reply
ProfProfit
ProfProfit May. 15 at 12:07 AM
$CBIO why the f did I not buy more at $17 a few days ago??? 🤬
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 13 at 6:04 PM
$CBIO Excellent article that nails exactly where CBIO stands right now. So if you want to update your CBIO knowledge or get acquainted with CBIO, this is a must read. https://everyticker.com/quote/CBIO/analysis/crescent-biopharma-s-189m-clinical-reset-three-shots-at-a-13b-valuation-nasdaq-cbio
0 · Reply
MorenitaScorp
MorenitaScorp May. 5 at 2:18 PM
$CBIO ⌚️
0 · Reply
PenkeInvesting
PenkeInvesting May. 4 at 4:20 PM
Fundamental analysis of $CBIO (CRESCENT BIOPHARMA, INC.) based on financial data and reported results. #CBIO
0 · Reply
lyonsa14
lyonsa14 May. 1 at 5:56 PM
$CBIO Looks like it’s falling in sympathy with Summit Therapeutics. https://www.fiercepharma.com/pharma/summit-pd-1vegf-interim-trial-miss-surprises-analysts-shares-tumble
0 · Reply
ProfProfit
ProfProfit May. 1 at 3:44 PM
$CBIO why the 30% drop today?
0 · Reply
Latest News on CBIO
Crescent Biopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:40 AM EDT - 18 hours ago

Crescent Biopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Crescent Biopharma Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:20 PM EDT - 5 days ago

Crescent Biopharma Transcript: Jefferies Global Healthcare Conference 2026

Crescent Biopharma to Present at June Investor Conferences

Jun 2, 2026, 4:15 PM EDT - 6 days ago

Crescent Biopharma to Present at June Investor Conferences

CBIO

Crescent Biopharma Transcript: AGM 2026

Jun 2, 2026, 9:00 AM EDT - 6 days ago

Crescent Biopharma Transcript: AGM 2026

Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright

2026-06-01T10:31:19.000Z - 7 days ago

Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright

CBIO

Crescent Biopharma Announces Grants of Inducement Awards

May 29, 2026, 4:15 PM EDT - 10 days ago

Crescent Biopharma Announces Grants of Inducement Awards

CBIO

Crescent Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 11:30 AM EDT - 13 days ago

Crescent Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

May 21, 2026, 5:30 PM EDT - 18 days ago

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

CBIO

Crescent Biopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 20, 2026, 2:30 PM EDT - 19 days ago

Crescent Biopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum

Crescent Biopharma Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 7:20 PM EDT - 26 days ago

Crescent Biopharma Transcript: Bank of America Global Healthcare Conference 2026

Crescent Biopharma to Present at May Investor Conferences

May 6, 2026, 7:30 AM EDT - 4 weeks ago

Crescent Biopharma to Present at May Investor Conferences

CBIO

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)

2026-04-29T21:25:20.000Z - 5 weeks ago

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)

CBIO

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Apr 29, 2026, 4:15 PM EDT - 5 weeks ago

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

CBIO

Crescent Biopharma Quarterly report: Q1 2026

Apr 29, 2026, 7:00 AM EDT - 5 weeks ago

Crescent Biopharma Quarterly report: Q1 2026

Crescent Biopharma Earnings release: Q1 2026

Apr 29, 2026, 7:00 AM EDT - 5 weeks ago

Crescent Biopharma Earnings release: Q1 2026

Crescent Biopharma Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Crescent Biopharma Proxy statement: Proxy filing

Crescent Biopharma Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Crescent Biopharma Proxy statement: Proxy filing

Crescent Biopharma Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Crescent Biopharma Proxy statement: Proxy filing

Crescent Biopharma management to meet with Cantor Fitzgerald

2026-04-08T20:50:50.000Z - 2 months ago

Crescent Biopharma management to meet with Cantor Fitzgerald

CBIO

Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 8:40 AM EDT - 3 months ago

Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026

Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:50 PM EST - 3 months ago

Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

2026-03-02T11:44:56.000Z - 3 months ago

Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

CBIO

Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year

2026-02-26T12:49:35.000Z - 3 months ago

Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year

CBIO

Crescent Biopharma sees cash runway into 2028

2026-02-26T12:48:53.000Z - 3 months ago

Crescent Biopharma sees cash runway into 2028

CBIO

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 26, 2026, 7:30 AM EST - 3 months ago

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

CBIO

Crescent Biopharma Annual report: Q4 2025

Feb 26, 2026, 7:30 AM EST - 3 months ago

Crescent Biopharma Annual report: Q4 2025

Crescent Biopharma Earnings release: Q4 2025

Feb 26, 2026, 7:30 AM EST - 3 months ago

Crescent Biopharma Earnings release: Q4 2025

Crescent Biopharma to Present at March Investor Conferences

Feb 23, 2026, 7:30 AM EST - 3 months ago

Crescent Biopharma to Present at March Investor Conferences

CBIO

Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial

2026-02-18T12:36:19.000Z - 3 months ago

Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial

CBIO

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

Feb 18, 2026, 7:30 AM EST - 3 months ago

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

CBIO

Crescent Biopharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 11:30 AM EST - 4 months ago

Crescent Biopharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:30 AM EST - 4 months ago

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

CBIO

Crescent Biopharma initiated with an Overweight at Piper Sandler

2026-01-28T11:36:53.000Z - 4 months ago

Crescent Biopharma initiated with an Overweight at Piper Sandler

CBIO

Crescent Biopharma initiated with a Buy at Guggenheim

2026-01-21T11:35:26.000Z - 4 months ago

Crescent Biopharma initiated with a Buy at Guggenheim

CBIO SMMT

Crescent Biopharma files to sell 19.71M shares of common stock for holders

2026-01-07T22:15:16.000Z - 5 months ago

Crescent Biopharma files to sell 19.71M shares of common stock for holders

CBIO

Crescent Biopharma announces regulatory clearance of IND applications

2026-01-05T12:16:19.000Z - 5 months ago

Crescent Biopharma announces regulatory clearance of IND applications

CBIO

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

Jan 5, 2026, 7:00 AM EST - 5 months ago

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

CBIO

Crescent Biopharma price target raised to $32 from $28 at Stifel

2025-12-04T20:35:38.000Z - 6 months ago

Crescent Biopharma price target raised to $32 from $28 at Stifel

CBIO

Crescent Biopharma Transcript: Partnership

Dec 4, 2025, 8:00 AM EST - 6 months ago

Crescent Biopharma Transcript: Partnership

Crescent Biopharma Press release: Partnership

Dec 4, 2025, 8:00 AM EST - 6 months ago

Crescent Biopharma Press release: Partnership

Crescent Biopharma Slides: Partnership

Dec 4, 2025, 8:00 AM EST - 6 months ago

Crescent Biopharma Slides: Partnership

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Dec 4, 2025, 6:35 AM EST - 6 months ago

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

CBIO

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Dec 4, 2025, 6:30 AM EST - 6 months ago

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

CBIO

Crescent Biopharma Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 4:30 AM EST - 7 months ago

Crescent Biopharma Transcript: Jefferies London Healthcare Conference 2025

Crescent Biopharma Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 1:20 PM EST - 7 months ago

Crescent Biopharma Transcript: Stifel 2025 Healthcare Conference

Crescent Biopharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 8:00 AM EST - 7 months ago

Crescent Biopharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Crescent Biopharma reports Q3 EPS ($1.27), two est. ($1.38)

2025-11-06T12:43:44.000Z - 7 months ago

Crescent Biopharma reports Q3 EPS ($1.27), two est. ($1.38)

CBIO

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:30 AM EST - 7 months ago

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

CBIO

Crescent Biopharma Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Crescent Biopharma Quarterly report: Q3 2025

Crescent Biopharma Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Crescent Biopharma Earnings release: Q3 2025

Crescent Biopharma to Present at November Investor Conferences

Nov 5, 2025, 7:30 AM EST - 7 months ago

Crescent Biopharma to Present at November Investor Conferences

CBIO

Crescent Biopharma Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 7 months ago

Crescent Biopharma Slides: Corporate Presentation

Crescent Biopharma to present preclinical data from CR-001

2025-11-04T14:16:54.000Z - 7 months ago

Crescent Biopharma to present preclinical data from CR-001

CBIO

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 4, 2025, 9:05 AM EST - 7 months ago

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

CBIO

Crescent Biopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 5:35 PM EDT - 9 months ago

Crescent Biopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Crescent Biopharma Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 1:00 PM EDT - 9 months ago

Crescent Biopharma Transcript: Cantor Global Healthcare Conference 2025

Crescent Biopharma Slides: Corporate Presentation

Sep 3, 2025, 6:00 PM EDT - 9 months ago

Crescent Biopharma Slides: Corporate Presentation

Crescent Biopharma to Present at September Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 10 months ago

Crescent Biopharma to Present at September Investor Conferences

CBIO

Crescent Biopharma initiated with a Buy at Jefferies

2025-08-25T08:45:09.000Z - 10 months ago

Crescent Biopharma initiated with a Buy at Jefferies

CBIO

Crescent Biopharma initiated with a Buy at H.C. Wainwright

2025-08-11T10:16:16.000Z - 10 months ago

Crescent Biopharma initiated with a Buy at H.C. Wainwright

CBIO

Crescent Biopharma reports Q2 EPS ($4.93)

2025-07-31T11:42:43.000Z - 11 months ago

Crescent Biopharma reports Q2 EPS ($4.93)

CBIO

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 31, 2025, 7:34 AM EDT - 11 months ago

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

CBIO

Crescent Biopharma Earnings release: Q2 2025

Jul 31, 2025, 7:00 AM EDT - 11 months ago

Crescent Biopharma Earnings release: Q2 2025

Crescent Biopharma Quarterly report: Q2 2025

Jul 31, 2025, 7:00 AM EDT - 11 months ago

Crescent Biopharma Quarterly report: Q2 2025

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

CBIO

Crescent Biopharma Slides: Corporate Presentation

Jul 8, 2025, 7:00 AM EDT - 11 months ago

Crescent Biopharma Slides: Corporate Presentation

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

CBIO

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Jun 5, 2025, 4:01 PM EDT - 1 year ago

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

May 16, 2025, 1:55 PM EDT - 1 year ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints David Lubner to Board of Directors

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

Mar 5, 2025, 11:20 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

CMRX

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Nov 6, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

Oct 29, 2024, 11:47 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Oct 29, 2024, 6:30 AM EDT - 1 year ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

Jul 25, 2024, 9:00 AM EDT - 2 years ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jun 4, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

May 29, 2024, 4:01 PM EDT - 2 years ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

May 6, 2024, 6:00 AM EDT - 2 years ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 25, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 27, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Feb 12, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Jan 4, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Dec 10, 2023, 12:00 PM EST - 2 years ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Nov 3, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

Oct 30, 2023, 12:00 PM EDT - 2 years ago

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

CBIO

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

Oct 20, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

Sep 6, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

MorenitaScorp
MorenitaScorp Jun. 8 at 1:58 AM
$CBIO ⌚️
0 · Reply
focafoca99
focafoca99 Jun. 3 at 1:26 PM
$CBIO recorded its annual meeting voting results, electing two Class II directors and approving key shareholder proposals.
0 · Reply
focafoca99
focafoca99 May. 22 at 12:14 AM
$CBIO previewed its ASCEND trial poster for the ASCO 2026 meeting.
0 · Reply
outlawinvestor1
outlawinvestor1 May. 16 at 10:04 AM
updated paragon family of extended life biologics. https://www.paragontherapeutics.com/ $APGE $SYRE $ORKA $JBIO $CBIO
1 · Reply
ProfProfit
ProfProfit May. 15 at 12:07 AM
$CBIO why the f did I not buy more at $17 a few days ago??? 🤬
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 13 at 6:04 PM
$CBIO Excellent article that nails exactly where CBIO stands right now. So if you want to update your CBIO knowledge or get acquainted with CBIO, this is a must read. https://everyticker.com/quote/CBIO/analysis/crescent-biopharma-s-189m-clinical-reset-three-shots-at-a-13b-valuation-nasdaq-cbio
0 · Reply
MorenitaScorp
MorenitaScorp May. 5 at 2:18 PM
$CBIO ⌚️
0 · Reply
PenkeInvesting
PenkeInvesting May. 4 at 4:20 PM
Fundamental analysis of $CBIO (CRESCENT BIOPHARMA, INC.) based on financial data and reported results. #CBIO
0 · Reply
lyonsa14
lyonsa14 May. 1 at 5:56 PM
$CBIO Looks like it’s falling in sympathy with Summit Therapeutics. https://www.fiercepharma.com/pharma/summit-pd-1vegf-interim-trial-miss-surprises-analysts-shares-tumble
0 · Reply
ProfProfit
ProfProfit May. 1 at 3:44 PM
$CBIO why the 30% drop today?
0 · Reply
stockanalysis_
stockanalysis_ May. 1 at 1:49 PM
Losers Today: $CREG $SKBL $CBIO $SDOT $BAFN Download this screener: https://stockanalysis.com/markets/losers/?ref=saveontrading
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 28 at 8:54 AM
$CBIO
0 · Reply
Estimize
Estimize Apr. 21 at 11:03 PM
Wall St is expecting -0.88 EPS for $CBIO Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/cbio?chart=historical&metric_name=eps&utm_c
0 · Reply
Jt11111
Jt11111 Apr. 21 at 7:36 PM
$CBIO something gotta be cooking
0 · Reply
stocktrade77
stocktrade77 Apr. 17 at 6:00 PM
$CBIO swing closed - banked , taken out most of it - just leaving rest for fun
0 · Reply
ProfProfit
ProfProfit Apr. 17 at 5:10 PM
$CBIO why no attention on this thing? It’s green almost everyday for a month now and literally doubled its value in that time
0 · Reply
SSRbenny
SSRbenny Apr. 17 at 3:45 AM
$CBIO anyone wanna tell me when the Markt cap became $500M????
0 · Reply
Jt11111
Jt11111 Apr. 14 at 7:33 PM
$CBIO liking this a lot!
0 · Reply
Stonski
Stonski Apr. 7 at 8:51 PM
$QNCX can we stop with the space X NONSENSE GUYS 😭😭 .. this is gonna be $CBIO 2.0 it’s gonna be a biotech company that takes over the ticker As for why it’s mooning today my guess will be the clean up of the financials ( debt free rn) n talks are heating up
0 · Reply
lyonsa14
lyonsa14 Apr. 1 at 11:01 PM
$CBIO Or, may be discussions regarding M&A. I suspect it’s either this or early data results are leaking out. This is just speculation. 
0 · Reply
lyonsa14
lyonsa14 Apr. 1 at 8:02 PM
$CBIO Just speculation, but likely insiders are seeing early data that looks promising. This is just a guess based on the rapid recent stock price increase. It’s more than obvious that it’s not a level playing field for small retail investors. Biotech investing is very difficult. 
0 · Reply